YOLFTbeta
Redhill Biopharma Ltd

Redhill Biopharma Ltd

RDHL · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.375USD-0.01 (-1.60%)

Price History

Full chart

Market Stats

Previous Close0.3811
Open0.37
Day Range0.37 – 0.3926
52-Week Range0.49 – 2.61
Volume35.19K
Market Cap3.04M
P/E (TTM)0.00
Forward P/E1428.57
EPS0.00
Dividend Yield0.00%
Beta4.95
50-Day Avg0.643
200-Day Avg0.9039

About

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Dror Ben-Asher
  • Employees13
  • Headquarters21 Ha?arba?a Street, Tel Aviv-Yafo, Israel, 6473921, USA
  • Websitehttps://www.redhillbio.com

Leadership

  • Mr. Dror Ben-AsherCo-Founder, Chairman & CEO · b. 1966
  • Mr. Razi IngberChief Financial Officer · b. 1984
  • Mr. Gilead Raday MPhil, MScChief Operating Officer · b. 1975
  • Mr. Adi FrishChief Corporate & Business Development Officer · b. 1970
  • Mr. Rick D. ScruggsChief Commercial Officer & Director · b. 1960
  • Dr. Mark L. Levitt M.D., Ph.D.Chief Scientific Officer
  • Ms. Alexandra OkmianSenior Business Development & Investor Relations Manager
  • Dr. Reza Fathi Ph.D.Senior Vice President of Research & Development · b. 1955
  • Mr. Guy Goldberg J.D.Chief Business Officer · b. 1976
  • Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory Affairs

Financials

Income Statement

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-23.00K16.00K12.00K7.01M3.00K101.00K4.01M8.36M6.29M64.36M85.76M61.80M6.53M8.04M286.00K
Growth (%)---30.43%-25.00%+58350.00%-99.96%+3266.67%+3867.33%+108.63%-24.75%+923.03%+33.25%-27.94%-89.43%+23.17%-96.44%
Cost of Revenue-7.88M9.03M10.76M1.05M22.00M30.54M2.13M2.84M2.26M36.89M49.41M33.34M3.46M3.19M-
Gross Profit-23.00K16.00K12.00K5.96M-22.00M-30.44M1.88M5.52M4.03M27.47M36.35M28.46M3.07M4.85M286.00K
Gross Margin-100.00%100.00%100.00%85.03%-733300.00%-30140.59%46.94%66.06%64.09%42.68%42.39%46.06%47.03%60.31%100.00%
Operating Expense-7.90M9.06M10.78M16.61M3.00K101.00K53.85M44.85M47.23M91.15M117.49M71.31M-9.56M19.46M8.20M
Operating Income-1.73M-7.87M-9.04M-10.77M-10.65M-22.00M-30.54M-51.97M-39.33M-43.20M-63.68M-81.14M-42.84M12.63M-14.61M-7.91M
Operating Margin--34230.43%-56500.00%-89766.67%-151.80%-733400.00%-30240.59%-1297.03%-470.47%-686.71%-98.95%-94.61%-69.33%193.45%-181.69%-2765.38%
EBITDA-2.55M-7.86M-9.02M-10.75M-10.62M-21.97M-30.50M-45.46M-38.73M-40.70M-54.98M-63.03M-22.18M26.27M-7.59M-7.65M
EBITDA Margin--34165.22%-56350.00%-89566.67%-151.41%-732200.00%-30197.03%-1134.59%-463.28%-646.97%-85.42%-73.50%-35.89%402.34%-94.42%-2675.52%
Net Income-2.54M-15.50M-10.33M-10.63M-10.71M-21.09M-29.37M-45.54M-38.82M-42.30M-76.17M-97.74M-71.67M23.92M-8.27M-429.00K
Net Income Margin--67404.35%-64537.50%-88566.67%-152.71%-703000.00%-29079.21%-1136.61%-464.35%-672.45%-118.36%-113.98%-115.97%366.25%-102.80%-150.00%
R&D736.00K5.41M6.46M8.10M12.70M17.77M25.24M32.97M24.86M17.42M16.49M29.50M7.28M3.53M1.59M2.02M
R&D as % of Total Revenue-23539.13%40343.75%67500.00%181.07%592366.67%24991.09%822.79%297.39%276.89%25.62%34.40%11.78%54.03%19.74%707.34%
Interest Expense876.00K65.00K1.48M14.00K22.00K12.00K7.00K77.00K167.00K439.42K12.45M16.57M41.33M367.00K55.00K19.00K
Interest Expense % of Total Revenue-282.61%9268.75%116.67%0.31%400.00%6.93%1.92%2.00%6.98%19.34%19.32%66.88%5.62%0.68%6.64%

Balance Sheet

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.51M20.19M20.10M14.34M28.86M66.83M74.21M57.34M62.41M74.10M180.24M181.19M158.87M23.05M18.04M25.34M
Total Liabilities12.10M1.40M1.08M2.42M3.85M6.75M11.51M12.28M11.22M14.10M166.38M172.31M207.27M20.98M22.73M21.08M
Total Equity-1.59M18.79M19.02M11.93M25.01M60.08M62.70M45.06M51.19M60.00M13.86M8.88M-48.40M2.07M-4.68M4.27M
Cash9.05M14.07M16.81M11.85M5.89M21.52M53.79M16.45M29.00M29.02M29.30M29.47M19.97M5.57M4.62M3.97M
Total Debt---------3.81M86.90M87.81M122.69M1.17M356.00K1.07M
Net Debt--14.07M-16.81M-11.85M-5.89M-21.52M-53.79M-16.45M-29.00M-25.21M57.61M58.34M102.72M-4.40M-4.26M-2.90M

Cash Flow

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.63M-4.69M-6.79M-8.44M-12.23M-17.83M-28.26M-44.77M-34.46M-40.75M-48.58M-65.05M-29.18M-35.82M-9.37M-9.65M
Investing Cash Flow-1.02M-4.77M2.98M1.13M-17.86M-21.19M24.47M-18.58M5.35M5.16M-35.65M-8.14M8.30M3.99K-9.00K1.69M
Financing Cash Flow11.09M13.84M6.55M2.28M24.37M54.79M36.02M25.65M41.76M35.51M84.37M73.46M11.45M21.38M8.42M7.32M
Capital Expenditure1.11M181.00K108.00K224.00K1.10M1.63M120.00K1.18M58.00K203.00K53.77M115.00K198.00K11.00K9.00K5.00K
Free Cash Flow-2.74M-4.87M-6.90M-8.66M-13.33M-19.46M-28.38M-45.95M-34.52M-40.95M-102.35M-65.16M-29.38M-35.83M-9.38M-9.66M
FCF to OCF167.89%103.86%101.59%102.66%109.04%109.17%100.42%102.64%100.17%100.50%210.69%100.18%100.68%100.03%100.10%100.05%

Earnings

Report DateFeb 27, 2013May 2, 2013Jul 22, 2013Nov 12, 2013Feb 25, 2014Apr 30, 2014Jul 23, 2014Nov 10, 2014Feb 28, 2015Apr 30, 2015Jul 29, 2015Nov 9, 2015Feb 25, 2016Apr 20, 2016Jul 26, 2016Nov 14, 2016Feb 23, 2017May 3, 2017Jul 25, 2017Nov 13, 2017Feb 22, 2018May 8, 2018Aug 30, 2018Nov 13, 2018Feb 26, 2019May 7, 2019Jul 23, 2019Nov 19, 2019Mar 4, 2020May 27, 2020Aug 13, 2020Nov 12, 2020Mar 18, 2021May 27, 2021Aug 26, 2021Nov 30, 2021Mar 17, 2022Jun 23, 2022Sep 23, 2022Nov 29, 2022Mar 27, 2023Apr 28, 2023Aug 17, 2023Nov 15, 2023Feb 12, 2024Apr 8, 2024Aug 29, 2024Nov 29, 2024Mar 31, 2025Apr 10, 2025Sep 5, 2025Dec 2, 2025Mar 12, 2026
EPS Estimate--450.00-440.00-620.00-500.00-0.44-380.00-500.00-0.60-465.00-463.33-505.00-0.42-510.00-576.67-526.67-693.33-0.57-620.00-636.67-0.60-463.33-0.44-413.33-0.38-346.67-346.67-292.50-237.50-600.00-90.00-185.00-0.24-278.00-248.00-282.00-430.00-30.00-0.03-10.000.00--0.00-0.03-0.03-30.000.000.000.000.000.000.00
EPS Actual-643.44-30.00-40.00-40.00-50.000.39-517.00-500.00-0.60-500.00-700.00-300.00-0.50-400.00-500.00-700.00-600.00-0.50-600.00-900.00-0.50-500.00-0.50-400.00-0.30-300.00-400.00-300.00-300.00-500.00-40.00-499.82-0.70-500.00-600.00-50.00-500.00-30.00-0.20-60.00-0.20-1.600.260.00-0.20-0.20-200.000.00-4.02-4.02-2.290.000.00
Surprise-93.33%90.91%93.55%90.00%188.64%-36.05%0.00%0.00%-7.53%-51.08%40.59%-19.05%21.57%13.30%-32.91%13.46%12.28%3.23%-41.36%16.67%-7.91%-13.64%3.23%21.05%13.46%-15.38%-2.56%-26.32%16.67%55.56%-170.17%-191.67%-79.86%-141.94%82.27%-16.28%0.00%-566.67%-500.00%-----566.67%-566.67%-566.67%------
Timing-After-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-market------

Key Statistics & Ratios

Market Cap3.04M
Enterprise Value413.10K
Trailing P/E0.00
Forward P/E1428.57
PEG Ratio0.00
Price / Sales10.63
Price / Book0.78
EPS0.00
Book Value0.838
Revenue (TTM)286.00K
Gross Profit (TTM)286.00K
EBITDA-7.79M
Profit Margin-150.00%
Operating Margin-2765.39%
Return on Equity-1708.61%
Return on Assets-22.79%
Shares Outstanding6.08M
Shares Float4.20M
Beta4.95
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 19,000.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
5.19%
Insiders
0.00%
Retail / Other
94.81%

Top Institutional Holders

  • Yorkville Advisors Global, LP
    122.13K2.01%
  • Gagnon Securities LLC
    88.41K1.45%
  • Citadel Advisors Llc
    65.32K1.07%
  • XTX Topco Ltd
    15.16K0.25%
  • StoneX Group Inc
    14.48K0.24%
  • TWO SIGMA SECURITIES, LLC
    13.02K0.21%
  • GAMMA Investing LLC
    6.96K0.11%
  • Rhumbline Advisers
    5.12K0.08%
  • Federation des caisses Desjardins du Quebec
    3.39K0.06%
  • UBS Group AG
    8260.01%
  • Mercer Global Advisors Inc.
    500.00%
  • Your Advocates Ltd., LLP
    190.00%
  • SBI Securities Co Ltd
    40.00%
  • Morgan Stanley - Brokerage Accounts
    10.00%
  • EverSource Wealth Advisors, LLC
    00.00%
  • Garton & Associates Financial Advisors LLC
    00.00%
  • Group One Trading, LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Yorkville Health Care Opportunities Cl F
    140.00%

Stock Splits

  • Aug 20, 20241:25
  • Mar 23, 20231:40